BASF has officially opened its new Good Manufacturing Practice (GMP) Solution Center in Wyandotte, Michigan, marking a strategic expansion of its capabilities in the biopharma and pharmaceutical ingredients sector. The facility represents a significant investment in high-quality production systems and cutting-edge technology designed to support the evolving needs of pharmaceutical customers worldwide.
The new center will strengthen BASF’s global network of GMP manufacturing sites, with advanced systems to ensure the consistent and tightly controlled production of bioprocessing ingredients and pharmaceutical excipients. These quality measures are critical in the pharmaceutical industry, where even minor deviations can impact safety, efficacy, and regulatory compliance.
Equipped with state-of-the-art cleanroom packaging and precision analytical testing, the site is designed to enable close customer collaboration. It also offers expanded manufacturing capabilities with the ability to exceed standard compendial limits and implement a validated control system for enhanced consistency and product performance.
Marion Kuhn, vice president of business management at BASF Pharma Solutions, emphasized that the new facility reflects the company’s long-term commitment to innovation and customer-centric development in both the biopharma and small molecule markets. She noted that the center will serve as a collaborative platform for global clients seeking customized solutions in GMP manufacturing.
Benjamin Knudsen, vice president of research North America at BASF Corporation, described the launch as a demonstration of BASF’s adaptability and continued pursuit of excellence in pharmaceutical innovation. The facility, he said, reinforces BASF’s role as a reliable partner capable of responding to increasingly complex customer demands.
The GMP Solution Center positions BASF to support faster product development timelines while maintaining the rigorous quality standards required in the life sciences industry.
